Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 18673245)

  • 1. Wnt signaling in renal cancer.
    Guillén-Ahlers H
    Curr Drug Targets; 2008 Jul; 9(7):591-600. PubMed ID: 18673245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Wnt signaling and cancer development: therapeutic implication.
    Paul S; Dey A
    Neoplasma; 2008; 55(3):165-76. PubMed ID: 18348648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MicroRNAs Associated with Von Hippel-Lindau Pathway in Renal Cell Carcinoma: A Comprehensive Review.
    Schanza LM; Seles M; Stotz M; Fosselteder J; Hutterer GC; Pichler M; Stiegelbauer V
    Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29165391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the Wnt/β-catenin signaling pathway in human cancers.
    Yao H; Ashihara E; Maekawa T
    Expert Opin Ther Targets; 2011 Jul; 15(7):873-87. PubMed ID: 21486121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the most upstream site of Wnt signaling pathway provides a strategic advantage for therapy in colorectal cancer.
    Qi J; Zhu YQ
    Curr Drug Targets; 2008 Jul; 9(7):548-57. PubMed ID: 18673240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IGFBP-4 activates the Wnt/beta-catenin signaling pathway and induces M-CAM expression in human renal cell carcinoma.
    Ueno K; Hirata H; Majid S; Tabatabai ZL; Hinoda Y; Dahiya R
    Int J Cancer; 2011 Nov; 129(10):2360-9. PubMed ID: 21207373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Wnt/Frizzled signaling in hepatocellular carcinoma.
    Lee HC; Kim M; Wands JR
    Front Biosci; 2006 May; 11():1901-15. PubMed ID: 16368566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic potential of targeting the Wnt/β-catenin signaling pathway in colorectal cancer.
    Cheng X; Xu X; Chen D; Zhao F; Wang W
    Biomed Pharmacother; 2019 Feb; 110():473-481. PubMed ID: 30530050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Wnt signaling as a therapeutic target for cancer.
    Herbst A; Kolligs FT
    Methods Mol Biol; 2007; 361():63-91. PubMed ID: 17172707
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The β-catenin/TCF complex as a novel target of resveratrol in the Wnt/β-catenin signaling pathway.
    Chen HJ; Hsu LS; Shia YT; Lin MW; Lin CM
    Biochem Pharmacol; 2012 Nov; 84(9):1143-53. PubMed ID: 22935447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic inactivation of Wnt inhibitory factor-1 plays an important role in bladder cancer through aberrant canonical Wnt/beta-catenin signaling pathway.
    Urakami S; Shiina H; Enokida H; Kawakami T; Tokizane T; Ogishima T; Tanaka Y; Li LC; Ribeiro-Filho LA; Terashima M; Kikuno N; Adachi H; Yoneda T; Kishi H; Shigeno K; Konety BR; Igawa M; Dahiya R
    Clin Cancer Res; 2006 Jan; 12(2):383-91. PubMed ID: 16428476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The emerging role of nuclear factor kappa B in renal cell carcinoma.
    Morais C; Gobe G; Johnson DW; Healy H
    Int J Biochem Cell Biol; 2011 Nov; 43(11):1537-49. PubMed ID: 21854869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor formation due to abnormalities in the beta-catenin-independent pathway of Wnt signaling.
    Kikuchi A; Yamamoto H
    Cancer Sci; 2008 Feb; 99(2):202-8. PubMed ID: 18271916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Wnt/beta-catenin/tcf signaling: a critical pathway in gastrointestinal tumorigenesis.
    Kolligs FT; Bommer G; Göke B
    Digestion; 2002; 66(3):131-44. PubMed ID: 12481159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic Value of the VHL, HIF-1α, and VEGF Signaling Pathway and Associated MAPK (ERK1/2 and ERK5) Pathways in Clear-Cell Renal Cell Carcinoma. A Long-Term Study.
    Salinas-Sánchez AS; Serrano-Oviedo L; Nam-Cha SY; Roche-Losada O; Sánchez-Prieto R; Giménez-Bachs JM
    Clin Genitourin Cancer; 2017 Dec; 15(6):e923-e933. PubMed ID: 28624320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An oncogenic hub: beta-catenin as a molecular target for cancer therapeutics.
    Takemaru KI; Ohmitsu M; Li FQ
    Handb Exp Pharmacol; 2008; (186):261-84. PubMed ID: 18491056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. VHL missense mutations in the p53 binding domain show different effects on p53 signaling and HIFα degradation in clear cell renal cell carcinoma.
    Razafinjatovo CF; Stiehl D; Deininger E; Rechsteiner M; Moch H; Schraml P
    Oncotarget; 2017 Feb; 8(6):10199-10212. PubMed ID: 28052007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic targets in the Wnt signaling pathway: Feasibility of targeting TNIK in colorectal cancer.
    Masuda M; Sawa M; Yamada T
    Pharmacol Ther; 2015 Dec; 156():1-9. PubMed ID: 26542362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Dual-role regulations of canonical Wnt/beta-catenin signaling pathway].
    Liu Y; Zhang CG; Zhou CY
    Beijing Da Xue Xue Bao Yi Xue Ban; 2010 Apr; 42(2):238-42. PubMed ID: 20396373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New avenues to target Wnt/β-catenin signaling.
    Verkaar F; Zaman GJ
    Drug Discov Today; 2011 Jan; 16(1-2):35-41. PubMed ID: 21111060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.